CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Cabozantinib

卡博替尼 杂质对照品Cabozantinib Impurities

52 个杂质条目52 impurity entries

本页汇总 卡博替尼 的 52 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 52 impurity reference standards of Cabozantinib. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 卡博替尼(Cabozantinib)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesDegradation kinetics study of cabozantinib by a novel stability-indicating LC method and identification of its major degradation products by LC/TOF-MS and LC-MS/MS
    Journal of pharmaceutical and biomedical analysis · 2014 · Wu C et al.  ·  PMID 24992215  ·  DOI
  2. 分析方法Analytical MethodsDevelopment and Validation of an LC-MS/MS Method for Simultaneous Quantification of Pazopanib, Cabozantinib, Sorafenib, Axitinib, Tivozanib, Sunitinib, and the Metabolites Sorafenib N-Oxide and Desethyl-Sunitinib in Human Plasma
    Pharmaceuticals (Basel, Switzerland) · 2026 · Greibe E et al.  ·  PMID 42653677  ·  DOI
  3. 分析方法Analytical MethodsSimultaneous determination of belzutifan and cabozantinib, oral agents for renal cell carcinoma, in human plasma using high-performance liquid chromatography
    Drug discoveries & therapeutics · 2026 · Gando Y, Yasu T  ·  PMID 42649089  ·  DOI
  4. 分析方法Analytical MethodsQuantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS/MS
    Biomedical chromatography : BMC · 2020 · Krens SD et al.  ·  PMID 31758580  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisOne-step synthesis of [(18) F]cabozantinib for use in positron emission tomography imaging of c-Met
    Journal of labelled compounds & radiopharmaceuticals · 2018 · Lien VT et al.  ·  PMID 28921623  ·  DOI

卡博替尼 —— 原料药与杂质对照品Cabozantinib — drug substance & impurities

共 53 个条目(含原料药本体)53 items incl. the drug substance
Cabozantinib structure
原料药 APIAPI
卡博替尼Cabozantinib
Cabozantinib
CAS No.849217-68-1
Chemical FormulaC28H24FN3O5
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity G structure
G
6-氯-1-羟基苯并三氮唑Cabozantinib Impurity G
Cabozantinib Impurity G
CAS No.26198-19-6
Chemical FormulaC6H4ClN3O
Purity>95%现货In stock
10mg25mg50mg100mg
Cabozantinib L-Malate structure
—
卡博替尼 L-苹果酸盐Cabozantinib L-Malate
Cabozantinib L-Malate
CAS No.1140909-48-3
Chemical FormulaC28H24FN3O5·C4H6O5
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 1 structure
1
卡博替尼杂质1Cabozantinib Impurity 1
Cabozantinib Impurity 1
CAS No.849221-94-9
Chemical FormulaC28H25N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity N3 structure
N3
卡波替尼杂质N3Cabozantinib Impurity N3
Cabozantinib Impurity N3
CAS No.651054-52-3
Chemical FormulaC19H18N2O4
Purity>95%现货In stock
10mg25mg50mg100mg
Cabozantinib Impurity 5 structure
5
卡博替尼杂质5Cabozantinib Impurity 5
Cabozantinib Impurity 5
CAS No.145591-80-6
Chemical FormulaC11H11NO3
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 6 structure
6
卡博替尼杂质6Cabozantinib Impurity 6
Cabozantinib Impurity 6
CAS No.849217-77-2
Chemical FormulaC22H20N2O6
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 7 structure
7
卡博替尼杂质7Cabozantinib Impurity 7
Cabozantinib Impurity 7
CAS No.748707-58-6
Chemical FormulaC17H16N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 8 structure
8
卡博替尼杂质8Cabozantinib Impurity 8
Cabozantinib Impurity 8
CAS No.1431468-36-8
Chemical FormulaC17H14F2N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 9 structure
9
卡博替尼杂质9Cabozantinib Impurity 9
Cabozantinib Impurity 9
CAS No.1621681-63-7
Chemical FormulaC28H24FN3O6
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 10 structure
10
卡博替尼杂质10Cabozantinib Impurity 10
Cabozantinib Impurity 10
CAS No.190728-24-6
Chemical FormulaC17H14N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 11 structure
11
卡博替尼杂质11Cabozantinib Impurity 11
Cabozantinib Impurity 11
CAS No.918642-61-2
Chemical FormulaC11H10FNO3
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 14 structure
14
卡博替尼杂质14Cabozantinib Impurity 14
Cabozantinib Impurity 14
CAS No.1175127-32-8
Chemical FormulaC12H13NO3
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 15 structure
15
卡博替尼杂质15Cabozantinib Impurity 15
Cabozantinib Impurity 15
CAS No.849217-48-7
Chemical FormulaC11H10FNO3
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 18 structure
18
卡博替尼杂质18Cabozantinib Impurity 18
Cabozantinib Impurity 18
CAS No.190728-25-7
Chemical FormulaC17H16N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 21 structure
21
卡博替尼杂质21Cabozantinib Impurity 21
Cabozantinib Impurity 21
CAS No.849217-49-8
Chemical FormulaC12H12FNO3
Purity>95%现货In stock
10mg25mg50mg100mg
Cabozantinib Impurity 22 structure
22
卡博替尼杂质22Cabozantinib Impurity 22
Cabozantinib Impurity 22
CAS No.213699-53-7
Chemical FormulaC15H17NO6
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 23 structure
23
卡博替尼杂质23Cabozantinib Impurity 23
Cabozantinib Impurity 23
CAS No.1628530-47-1
Chemical FormulaC27H22FN3O5
Purity>95%现货In stock
10mg25mg50mg100mg
Cabozantinib Impurity 23 structure
23
卡博替尼杂质23Cabozantinib Impurity 23
Cabozantinib Impurity 23
CAS No.2439164-91-5
Chemical FormulaC39H34N4O8
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 24 structure
24
卡博替尼杂质24Cabozantinib Impurity 24
Cabozantinib Impurity 24
CAS No.1628530-42-6
Chemical FormulaC27H22FN3O5
Purity>95%现货In stock
10mg25mg50mg100mg
Cabozantinib Impurity 30 structure
30
卡博替尼杂质30Cabozantinib Impurity 30
Cabozantinib Impurity 30
CAS No.261783-72-6
Chemical FormulaC12H13NO3
Purity>95%现货In stock
10mg25mg50mg100mg
Cabozantinib Impurity 32 structure
32
卡博替尼杂质32Cabozantinib Impurity 32
Cabozantinib Impurity 32
CAS No.202917-04-2
Chemical FormulaC17H16N2O3
Purity>95%现货In stock
10mg25mg50mg100mg
Cabozantinib Impurity 33 structure
33
卡博替尼杂质33Cabozantinib Impurity 33
Cabozantinib Impurity 33
CAS No.775514-98-2
Chemical FormulaC13H16N2O2
Purity>95%现货In stock
10mg25mg50mg100mg
Cabozantinib Impurity 38 structure
38
卡博替尼杂质38Cabozantinib Impurity 38
Cabozantinib Impurity 38
CAS No.352-15-8
Chemical FormulaC6H4FNO
Purity>95%现货In stock
10mg25mg50mg100mg
Cabozantinib Impurity 42 structure
42
卡博替尼杂质42Cabozantinib Impurity 42
Cabozantinib Impurity 42
CAS No.95262-10-5
Chemical FormulaC9H8FNO3
Purity>95%现货In stock
10mg25mg50mg100mg
Cabozantinib Impurity 45 structure
45
卡博替尼杂质45Cabozantinib Impurity 45
Cabozantinib Impurity 45
CAS No.1071574-51-0
Chemical FormulaC10H13NO3
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 46 structure
46
卡博替尼杂质46Cabozantinib Impurity 46
Cabozantinib Impurity 46
CAS No.1247859-37-5
Chemical FormulaC11H10FNO3
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 47 structure
47
卡博替尼杂质47Cabozantinib Impurity 47
Cabozantinib Impurity 47
CAS No.113136-79-1
Chemical FormulaC11H10ClNO3
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 48 structure
48
卡博替尼杂质48Cabozantinib Impurity 48
Cabozantinib Impurity 48
CAS No.202916-99-2
Chemical FormulaC17H15NO3
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 49 structure
49
卡博替尼杂质49Cabozantinib Impurity 49
Cabozantinib Impurity 49
CAS No.190728-26-8
Chemical FormulaC17H14N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 50 structure
50
卡博替尼杂质50Cabozantinib Impurity 50
Cabozantinib Impurity 50
CAS No.202917-05-3
Chemical FormulaC17H14N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 51 structure
51
卡博替尼杂质51Cabozantinib Impurity 51
Cabozantinib Impurity 51
CAS No.2354-89-4
Chemical FormulaC10H10FNO
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 54 structure
54
卡博替尼杂质54Cabozantinib Impurity 54
Cabozantinib Impurity 54
CAS No.99878-79-2
Chemical FormulaC11H10ClNO2
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 61 structure
61
卡博替尼杂质61Cabozantinib Impurity 61
Cabozantinib Impurity 61
CAS No.406-00-8
Chemical FormulaC6H6FNO
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 62 structure
62
卡博替尼杂质62Cabozantinib Impurity 62
Cabozantinib Impurity 62
CAS No.332-07-0
Chemical FormulaC12H8F2N2
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 63 structure
63
卡博替尼杂质63Cabozantinib Impurity 63
Cabozantinib Impurity 63
CAS No.326-04-5
Chemical FormulaC12H8F2N2O
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 64 structure
64
卡博替尼杂质64Cabozantinib Impurity 64
Cabozantinib Impurity 64
CAS No.332-06-9
Chemical FormulaC12H10F2N2
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 65 structure
65
卡博替尼杂质65Cabozantinib Impurity 65
Cabozantinib Impurity 65
CAS No.2840522-80-5
Chemical FormulaC28H25ClFN3O5
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 69 structure
69
卡博替尼杂质69Cabozantinib Impurity 69
Cabozantinib Impurity 69
CAS No.1677-29-8
Chemical FormulaC15H12F2N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 71 structure
71
卡博替尼杂质71Cabozantinib Impurity 71
Cabozantinib Impurity 71
CAS No.35654-56-9
Chemical FormulaC11H10ClNO2
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 72 structure
72
卡博替尼杂质72Cabozantinib Impurity 72
Cabozantinib Impurity 72
CAS No.598-10-7
Chemical FormulaC5H6O4
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 74 structure
74
卡博替尼杂质74Cabozantinib Impurity 74
Cabozantinib Impurity 74
CAS No.2840522-81-6
Chemical FormulaC35H30N4O7
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 75 structure
75
卡博替尼杂质75Cabozantinib Impurity 75
Cabozantinib Impurity 75
CAS No.1628530-37-9
Chemical FormulaC21H18N2O9S
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 76 structure
76
卡博替尼杂质76Cabozantinib Impurity 76
Cabozantinib Impurity 76
CAS No.1355031-15-0
Chemical FormulaC16H14N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 78 structure
78
卡博替尼杂质78Cabozantinib Impurity 78
Cabozantinib Impurity 78
CAS No.1628530-38-0
Chemical FormulaC28H24FN3O6
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 79 structure
79
卡博替尼杂质79Cabozantinib Impurity 79
Cabozantinib Impurity 79
CAS No.1628530-41-5
Chemical FormulaC28H24FN3O6
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 81 structure
81
卡博替尼杂质81Cabozantinib Impurity 81
Cabozantinib Impurity 81
CAS No.1628530-45-9
Chemical FormulaC28H24FN3O9S
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 82 structure
82
卡博替尼杂质82Cabozantinib Impurity 82
Cabozantinib Impurity 82
CAS No.849217-60-3
Chemical FormulaC17H15FN2O3
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 88 structure
88
卡博替尼杂质88Cabozantinib Impurity 88
Cabozantinib Impurity 88
CAS No.1905820-17-8
Chemical FormulaC17H14F2N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 89 structure
89
卡博替尼杂质89Cabozantinib Impurity 89
Cabozantinib Impurity 89
CAS No.163156-90-9
Chemical FormulaC7H11BrO4
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 93 structure
93
卡博替尼杂质93Cabozantinib Impurity 93
Cabozantinib Impurity 93
CAS No.3052225-80-3
Chemical FormulaC28H24FN3O5
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 94 structure
94
卡博替尼杂质94Cabozantinib Impurity 94
Cabozantinib Impurity 94
CAS No.3041956-77-5
Chemical FormulaC56H49F2N6O10+·Cl-
Purity>95%询价On request
10mg25mg50mg100mg
Cabozantinib Impurity 95 structure
95
卡博替尼杂质95Cabozantinib Impurity 95
Cabozantinib Impurity 95
CAS No.3138175-24-0
Chemical FormulaC32H30FN3O10
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

卡博替尼 —— 研究文献与合成路线Cabozantinib — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 卡博替尼 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Cabozantinib. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Degradation kinetics study of cabozantinib by a novel stability-indicating LC method and identification of its major degradation products by LC/TOF-MS and LC-MS/MS
    Wu C, Xu X, Feng C, et al. · Journal of pharmaceutical and biomedical analysis · 2014 · 被引 18cited 18
  2. Cabozantinib selectively induces proteasomal degradation of p53 somatic mutant Y220C and impedes tumor growth
    Lv FL, Zhang L, Ji C, et al. · The Journal of biological chemistry · 2025 · 被引 3cited 3
  3. Cabozantinib prevents AGEs-induced degradation of type 2 collagen and aggrecan in human chondrocytes
    Dong Y, Lin L, Ji Y, et al. · Aging · 2023 · 被引 3cited 3

合成路线文献Synthetic-route papers

  1. Design, synthesis and biological evaluations of novel VEGFR-2 inhibitors based on Fruquintinib and Cabozantinib
    Ding X, Wei H, Ye M, et al. · Molecular diversity · 2026
  2. Design, Synthesis and In Vitro Investigation of Cabozantinib-Based PROTACs to Target c-Met Kinase
    Sachkova AA, Andreeva DV, Tikhomirov AS, et al. · Pharmaceutics · 2022
  3. trans-Fluorine Effect in Cyclopropane: Diastereoselective Synthesis of Fluorocyclopropyl Cabozantinib Analogs
    Veliks J, Videja M, Kinens A, et al. · ACS medicinal chemistry letters · 2020

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

卡博替尼 杂质谱研究要点Cabozantinib — impurity profiling notes

下面这些是拿到 卡博替尼 的 53 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 53 impurity entries for Cabozantinib, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances